Sotorasib (AMG 510) is an investigational oral KRAS G12C inhibitor designed to block the abnormal proliferative action of mutant KRAS protein. It is under investigation for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation.

If you have a Hayes login, click here to view the full report on the Knowledge Center.